



Investing in the State of Innovation

For Immediate Release:

Date: December 17, 2014

Contacts:

Angus G. McQuilken, VP for Marketing and Communications

Cell: (617) 921-7749

amcquilken@masslifesciences.com

MASSACHUSETTS LIFE SCIENCES CENTER ANNOUNCES NEW APPOINTEE TO BOARD OF DIRECTORS

BioInnovation President and LabCentral Co-Founder Peter Parker joins Board of Directors

Waltham, MA – The Massachusetts Life Sciences Center (MLSC) announced today that Governor Deval Patrick has appointed Peter Parker, President of BioInnovation, to the MLSC Board of Directors.

The MLSC's seven member Board of Directors, appointed by the Governor and co-chaired by Secretaries Gregory Bialecki (Housing and Economic Development) and Glen Shor (Administration and Finance), oversees the agency's operations and programs.

Through the MLSC, Massachusetts is investing \$1 billion over 10 years in the growth of the state's life sciences ecosystem. These investments are being made under the Massachusetts Life Sciences Initiative, proposed by Governor Deval Patrick in 2007, and passed by the State Legislature and signed into law by Governor Patrick in 2008.

"Peter Parker is a champion for our state's thriving life sciences community, and he will be a terrific addition to the Life Sciences Center's Board of Directors," said Governor Patrick. "The Commonwealth is fortunate to have his entrepreneurial leadership and financial expertise at the table to help guide the Center's investment decisions as we continue the successful implementation of the Massachusetts Life Sciences Initiative."

For the past three decades, Peter has been a valuable asset to the life sciences industry. He has dedicated a significant amount of his time over the years to early stage company foundation, funding and growth and he has been an equity investor in over 30 companies. The sectors where he has invested extensively include tools, devices, diagnostics, and therapeutics. Peter served as CEO of Cequent Pharmaceuticals, which was sold to Marina Biotech in 2010. He has invested in 12 local start-ups including Boston Heart Diagnostics (Chairman), Klio Health, Veritas Genetics, 5G Bio, Deltix, Nova Molecular, BioEssences, Hope Dx, and

AbVitro. Peter managed worldwide R&D at AMAX Inc, a Fortune 50 industrial company. Peter has played a major role in the greater Boston/Cambridge healthcare start-up community for the past eight years. At MassChallenge, he has been deemed an 'all-star' in the healthcare and life sciences sectors. Mr. Parker has also been a peer reviewer for the Massachusetts Life Sciences Center, assisting as a volunteer in the evaluation of program applications and investment opportunities.

Mr. Parker has served as President of BioInnovation, LLC, a Cambridge, MA based provider of start-up capital and services to life sciences companies, since August 2010. In 2012, he became one of three co-founders of LabCentral, Inc, a new non-profit for companies who need shared laboratory space in Kendall Square. Mr. Parker also currently serves as a senior advisor to Ampersand Capital Partners, where he previously served as a General Partner from 1988-2006 and helped launch their healthcare franchise.

"I have spent the last 30 years helping innovators turn ground-breaking science into sustainable businesses," stated Mr. Parker. "Having worked on various projects with the Life Sciences Center over the past several years, I am constantly impressed with the impact of Governor Patrick's Initiative for life science entrepreneurs within the Commonwealth. It is an honor for me to accept the Governor's invitation to work even more closely with the MLSC's talented staff."

Mr. Parker will fill the seventh seat on the board. Other Board members (other than the co-chairs) include President and CEO of the Dana-Farber Cancer Institute, Edward J. Benz Jr., M.D., President of The University of Massachusetts, Robert L. Caret, President and CEO of Infinity Pharmaceuticals, Inc., Adelene Perkins, Ph.D and Director and Chief Scientific Officer of Cytonome/ST, Lydia Villa-Komaroff, Ph.D.

"We are so pleased to welcome Peter Parker as the newest member of our Board of Directors," said Susan Windham-Bannister, Ph.D., President & CEO of the MLSC. "The Board is the final arbiter of all of our investment decisions, so we rely on these experts to ensure that the Center is making the best use of the public dollars that are under our stewardship. We greatly appreciate Peter's willingness to add his strong financial knowledge and extensive experience with early-stage companies to the leadership of the Life Sciences Initiative."

About the Massachusetts Life Sciences Center

The Massachusetts Life Sciences Center (MLSC) is an investment agency that supports life sciences innovation, research, development and commercialization. The MLSC is charged with implementing a 10-year, \$1-billion, state-funded investment initiative. These investments create jobs and support advances that improve health and well-being. The MLSC offers the nation's most comprehensive set of incentives and collaborative programs targeted to the life sciences ecosystem. These programs propel the growth that has made Massachusetts the global leader in life sciences. The MLSC creates new models for collaboration and partners with organizations, both public and private, around the world to promote innovation in the life sciences. For more information, visit www.masslifesciences.com.

###